Evidence map›Paper›PMID 33960213›Full record

ArticleNanomedicine (London, England)2021

A novel gene therapy for neurodegenerative Lafora disease via

Hari Priya Vemana, Aishwarya Saraswat, Shraddha Bhutkar, Ketan Patel, Vikas V Dukhande

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Trehalose Treatment in Zebrafish Model of Lafora Disease.International journal of molecular sciences · 2022
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hari Priya VemanaDepartment of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11439, USA.
Aishwarya SaraswatDepartment of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11439, USA.
Shraddha BhutkarDepartment of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11439, USA.
Ketan PatelDepartment of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11439, USA.
Vikas V DukhandeDepartment of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11439, USA.ORCID 0000-0002-9288-715X

Funding

Clues from a rare neurodegenerative disease towards target identification for diabetes mellitusSC2GM125550 · NIGMS · ST. JOHN'S UNIVERSITY · PI DUKHANDE, VIKAS VASUDEO · 2018 to 2020
$492k
NIGMS NIH HHS SC2 GM125550
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lafora DiseasePropanolaminesGenetic TherapyHEK293 CellsHumansProtein Tyrosine Phosphatases, Non-Receptor1,2-dilinoleyloxy-3-dimethylaminopropaneEPM2A protein, humanPropanolaminesProtein Tyrosine Phosphatases, Non-ReceptorDLinDMA liposomesgene deliverygene therapyLafora diseaselaforinneurodegenerative disordersrare diseases

Identifiers

PMID33960213
PMCPMC8162161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.